Please provide your email address to receive an email when new articles are posted on . A new artemether-lumefantrine dispersible tablet was just as effective as the crushed standard tablet in ...

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV Dolutegravir is the first ...

* GSK - DOLUTEGRAVIR IS FIRST INTEGRASE INHIBITOR AVAILABLE AS A DISPERSIBLE TABLET FOR CHILDREN WEIGHING AT LEAST 3KG AND FROM FOUR WEEKS OF AGE Source text for Eikon: Further company coverage: Sign ...

Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...

The US Food and Drug Administration (FDA) has approved the first dispersible tablet formulation of dolutegravir (Tivicay PD, ViiV Healthcare) to treat HIV-1 infection in children at least 4 weeks old ...

* VIIV HEALTHCARE -TIVICAY PD, EXTENDED INDICATION OF EXISTING TIVICAY 50MG FILM-COATED TABLET ARE CURRENTLY UNDER REVIEW BY EUROPEAN MEDICINES AGENCY * VIIV HEALTHCARE - DOLUTEGRAVIR IS 1ST INTEGRASE ...